Triple

T22796788
Position Surface form Disambiguated ID Type / Status
Subject CDK6 E564269 entity
Predicate isDrugTargetOf P37016 FINISHED
Object abemaciclib
Abemaciclib is an oral anticancer drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
 E1556480 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: abemaciclib | Statement: [CDK6, isDrugTargetOf, abemaciclib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: abemaciclib
Context triple: [CDK6, isDrugTargetOf, abemaciclib]
  • A. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • B. dalpiciclib
    Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
  • C. trilaciclib
    Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
  • D. lapatinib
    Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
  • E. Lynparza
    Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: abemaciclib
Triple: [CDK6, isDrugTargetOf, abemaciclib]
Generated description
Abemaciclib is an oral anticancer drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: abemaciclib
Target entity description: Abemaciclib is an oral anticancer drug that selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • A. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • B. dalpiciclib
    Dalpiciclib is an investigational small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) being developed primarily for the treatment of hormone receptor–positive breast cancer.
  • C. trilaciclib
    Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor used to protect bone marrow from chemotherapy-induced damage in patients with certain cancers.
  • D. lapatinib
    Lapatinib is an oral small-molecule tyrosine kinase inhibitor used primarily to treat HER2-positive breast cancer.
  • E. Lynparza
    Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2458185f88190b0045227ee420411 completed April 17, 2026, 2:36 p.m.
NER Named-entity recognition batch_69f17cd9b3c0819096050f43a829ec0d completed April 29, 2026, 3:36 a.m.
NED1 Entity disambiguation (via context triple) batch_6a0ba7a098488190ac57cf88793a456c completed May 18, 2026, 11:58 p.m.
NEDg Description generation batch_6a0ba8bb77bc81909c5422f9d73c1e70 completed May 19, 2026, 12:03 a.m.
NED2 Entity disambiguation (via description) batch_6a0ba94752c48190a8892cac5ef862b2 completed May 19, 2026, 12:05 a.m.
Created at: April 17, 2026, 3:30 p.m.